BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target

BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.The price target implies an upside of 199.8% from the Sep 24 close of $59.38.Key takeaways from the analyst noteStrong Safety Profile of REZPEG: Nektar Therapeutics' lead drug, REZPEG, has demonstrated a…